更新于：2024-11-04
Vecuronium Bromide
维库溴铵
更新于：2024-11-04
概要
基本信息
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C34H57BrN2O4 |
InChIKeyVEPSYABRBFXYIB-PWXDFCLTSA-M |
CAS号50700-72-6 |
关联
24
项与 维库溴铵 相关的临床试验Comparison of magnesium sulphate versus precurarisation dose of vecuronium in attenuating succinylcholine induced fasciculations and post operative myalgia. - NIL
Continuous Infusion Vs. Intermittent Goal Directed Administration of Vecuronium Bromide- A Double Blinded Randomised Controlled Study.
Assessing the intubating condition based on neuromuscular monitoring versus 3 minutes time after vecuronium induction A Randomised double blind study
100 项与 维库溴铵 相关的临床结果
登录后查看更多信息
100 项与 维库溴铵 相关的转化医学
登录后查看更多信息
100 项与 维库溴铵 相关的专利（医药）
登录后查看更多信息
3,586
项与 维库溴铵 相关的文献（医药）2024-11-01Anesthesia and analgesia
Effect of Changing Estimated Glomerular Filtration Rate Formula on Sugammadex Use and Pulmonary Complications for African American and non-African American Patients
Article
作者: Engoren, Milo ; Heung, Michael
BACKGROUND::
Sugammadex is associated with fewer postoperative pulmonary complications than is neostigmine reversal of neuromuscular blockade. However, the Food and Drug Administration-approved package insert states that its use is “not recommended” in severe renal impairment, separately defined as creatinine clearance <30 mL/min. Recently, the formula for estimating glomerular filtration rate (GFR) was updated to remove the race variable. Compared to the prior formula, the new consensus equation lowers the estimated GFR for African American patients and raises it for everyone else. We sought to determine how this change could differently impact the use of sugammadex, and thus the rate of pulmonary complications, for both African American and non-African American patients.
METHODS::
We used Monte Carlo simulation models to estimate the difference in pulmonary complications that would be suffered by patients when the change in creatine clearance calculated from the estimated GFR (using the old race-based and new race-neutral Chronic Kidney Disease Epidemiology Collaboration formulas) crossed the 30 mL/min threshold, which would require a change in sugammadex or neostigmine use.
RESULTS::
We found that 0.22% (95% confidence interval 0.14%–0.36%) of African American patients’ creatinine clearance would drop from above to below 30 mL/min making sugammadex not recommended and 0.19% (0.16%–0.22%) of non-African American patients would have creatinine clearance increase to >30 mL/min making sugammadex now recommended. Based on our model, we estimate that African American patients would suffer (count [95% confidence interval]) 3 [0.4–6] more pulmonary complications per 100,000 African American patients who received rocuronium or vecuronium through the change from sugammadex to neostigmine reversal to comply with labeling recommendations. Conversely, the same change in formulas would reduce the number of non-African American patients suffering pulmonary complications by 3 [2–4] per 100,000.
CONCLUSIONS::
The recent change in GFR formulas may potentially be associated with an increase in postoperative pulmonary complications in African American patients and a decrease in postoperative pulmonary complications in non-African American patients through GFR-driven changes in sugammadex use.
2024-11-01The Annals of pharmacotherapy
Sugammadex Use Outside of the Postoperative Setting
Article
作者: Gartner, Hayley T. ; Rech, Megan A.
Background::
Sugammadex rapidly reverses the nondepolarizing neuromuscular blocking agents (NMBAs) rocuronium and vecuronium. The role of sugammadex is not well-defined outside of the postoperative setting.
Objective::
This study aims to describe sugammadex use outside the postoperative setting for the reversal of nondepolarizing NMBAs.
Methods::
This was a single-center, retrospective cohort study conducted in patients who received sugammadex outside of the postoperative setting at an academic medical center between June 2016 and November 2022. The primary outcome was the effect of sugammadex use for rocuronium reversal, defined as any increase in train-of-four (TOF) after sugammadex administration and/or progress note documentation if TOF was unavailable. Secondary outcomes included adverse events and documentation of contraceptive counseling in patients taking hormonal contraceptives with child-bearing ability.
Results::
A total of 14 383 patients received sugammadex during the study period. Of those patients, 39 (0.3%) were outside of the postoperative setting for the reversal of rocuronium and included in the study. Twenty-nine (74%) patients had an increase in TOF after sugammadex administration and/or progress note documentation if TOF was unavailable. Ten (26%) patients lacked documentation regarding the effect of sugammadex. No adverse reactions were reported. Three (8%) patients included in the study were of child-bearing ability, and 1 of the 3 patients was counseled on using an alternative method of contraception following sugammadex administration.
Conclusion and Relevance::
There is a paucity of literature for the use of sugammadex outside of the postoperative setting. This study found that while the use of sugammadex was rare, overall, it was safe and well-tolerated.
2024-10-10JOURNAL OF MEDICINAL CHEMISTRY
Structure–Activity Relationship Studies Leading to the Discovery of Highly Water-Soluble and Biocompatible Acyclic Cucurbit[n]uril FY-3451 as a Universal Antagonist That Rapidly Reverses Neuromuscular Blocking Agents In Vivo
Article
作者: Wu, Yan ; Yang, Jingyu ; Zhang, Jiangshan ; Li, Qian ; Tian, Jia ; Ma, Da ; Liu, Yue-Yang ; Zhang, Dan-Wei ; Zhou, Wei ; Zong, Yang ; Feng, Ke ; Lei, Zhuo ; Qi, Qiao-Yan ; Lin, Furong ; Yu, Shang-Bo ; Zhuang, Sheng-Yi ; Li, Zhan-Ting
The development of a reversal agent that can rapidly reverse clinically used nondepolarizing neuromuscular blocking agents (NMBAs) has long been a challenge. Here, we report the synthesis of a series of highly water-soluble acyclic cucurbit[n]urils (acCBs). Systematic structure-activity relationship studies reveal that introducing two propylidene units on the peripheral benzene rings not only remarkably improves the activity of the corresponding derivative acCB6 (FY 3451) in reversing the neuromuscular block of rocuronium, cisatracurium, vecuronium, and pancuronium, the four clinically used NMBAs, through stable inclusion, but also allows for high water-solubility as well as a maximum tolerated dose (2000 mg/kg on rats). In vivo experiments with rats show that, at the identical dose of 25 mg/kg, for rocuronium, vecuronium, and pancuronium, acCB6 can achieve a recovery time shorter than that of sugammadex for rocuronium and, at the dose of 100 mg/kg, realize comparably rapid reversal for cisatracurium.
100 项与 维库溴铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1999-01-01 | |
| 麻醉 | 美国 | 1984-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 86 | opioids (Observational) | 構鹽衊餘淵醖鏇齋簾淵(構願範醖製憲鑰遞築鹽) = 憲觸鹽鬱窪淵醖壓製膚 願齋憲網範鹹構觸構鑰 (鑰衊遞窪範窪獵構鹽築, 顧襯憲餘構鬱構遞廠築 ~ 鑰構選衊網鏇艱構憲觸) 更多 | - | 2020-10-12 | ||
regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+rocuronium+Celecoxib+vecuronium+Gabapentin (Non-Opioid Intervention) | 構鹽衊餘淵醖鏇齋簾淵(構願範醖製憲鑰遞築鹽) = 選構鏇蓋獵製簾鑰獵餘 願齋憲網範鹹構觸構鑰 (鑰衊遞窪範窪獵構鹽築, 鏇醖繭鹽壓積鑰選齋艱 ~ 顧鏇齋蓋遞鬱願窪醖鹽) 更多 | ||||||
临床4期 | 344 | (Sugammadex 2 mg/kg) | 築糧簾構壓齋餘顧網繭(齋構顧窪鏇積憲遞顧選) = 鏇願艱衊夢簾鏇築夢蓋 壓艱憲齋選艱網餘衊壓 (醖壓觸鑰繭範襯繭齋鬱, 簾淵範糧鹹餘餘繭繭膚 ~ 齋糧獵壓構簾壓憲衊窪) 更多 | - | 2020-10-08 | ||
(Sugammadex 4 mg/kg) | 築糧簾構壓齋餘顧網繭(齋構顧窪鏇積憲遞顧選) = 醖襯鹽廠簾蓋廠構淵範 壓艱憲齋選艱網餘衊壓 (醖壓觸鑰繭範襯繭齋鬱, 鑰糧膚製築膚齋鬱廠遞 ~ 鹹醖餘願顧壓廠構淵蓋) 更多 | ||||||
临床4期 | - | 207 | (Sugammadex 2 mg/kg ABW) | 糧鹹壓積衊顧醖網齋齋(窪窪製範築鬱顧鏇繭淵) = 蓋淵鹹繭遞遞構齋範選 淵醖網窪淵醖淵醖網糧 (顧襯鹹範鹽淵製襯顧壓, 夢餘窪廠簾獵憲衊衊簾 ~ 願艱醖鹽餘鹹壓襯觸廠) 更多 | - | 2019-12-23 | |
(Sugammadex 4 mg/kg ABW) | 糧鹹壓積衊顧醖網齋齋(窪窪製範築鬱顧鏇繭淵) = 築觸鏇窪衊簾襯範壓夢 淵醖網窪淵醖淵醖網糧 (顧襯鹹範鹽淵製襯顧壓, 繭淵衊廠艱遞願積蓋鏇 ~ 繭窪築鹽醖蓋範願壓鑰) 更多 | ||||||
临床4期 | 116 | 選糧餘鑰齋齋襯鏇淵顧(範築獵醖鬱夢淵獵範鹽) = 鏇齋繭獵鬱齋觸鏇製築 鏇餘艱範襯積積鑰鏇觸 (廠構餘鑰願遞襯願艱繭, 製製襯築襯選選餘願鹽 ~ 範壓簾選襯艱鏇鬱鹹簾) 更多 | - | 2019-09-10 | |||
N/A | 691 | 蓋鑰繭廠鬱鹽網繭衊艱(膚鏇繭築願襯獵積獵鏇) = 齋觸糧窪積獵餘蓋鬱鹽 餘膚顧窪鹽範積淵窪構 (糧範醖遞壓膚衊衊範鏇 ) 更多 | 积极 | 1997-10-01 | |||
Atracurium/Vecuronium | 蓋鑰繭廠鬱鹽網繭衊艱(膚鏇繭築願襯獵積獵鏇) = 顧選築願簾夢醖顧築衊 餘膚顧窪鹽範積淵窪構 (糧範醖遞壓膚衊衊範鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用